Search Results

There are 39397 results for: content related to: The selective mu-opioid receptor antagonist adl5510 reduces levodopa-induced dyskinesia without affecting antiparkinsonian action in mptp-lesioned macaque model of Parkinson's disease

  1. You have free access to this content
    Poster Presentations

    Movement Disorders

    Volume 27, Issue S1, June 2012, Pages: S1–S523,

    Version of Record online : 19 JUN 2012, DOI: 10.1002/mds.25051

  2. Abstracts of The Movement Disorder Society's Twelfth International Congress of Parkinson's Disease and Movement Disorders

    Movement Disorders

    Volume 23, Issue S1, 15 May 2008, Pages: S1–S422,

    Version of Record online : 28 MAY 2008, DOI: 10.1002/mds.22133

  3. Dual κ-agonist/μ-antagonist opioid receptor modulation reduces levodopa-induced dyskinesia and corrects dysregulated striatal changes in the nonhuman primate model of Parkinson disease

    Annals of Neurology

    Volume 77, Issue 6, June 2015, Pages: 930–941, Lisa F. Potts, Eun S. Park, Jong-Min Woo, Bhagya L. Dyavar Shetty, Arun Singh, Steven P. Braithwaite, Michael Voronkov, Stella M. Papa and M. Maral Mouradian

    Version of Record online : 27 MAR 2015, DOI: 10.1002/ana.24375

  4. You have free access to this content
    Poster Presentations

    Movement Disorders

    Volume 30, Issue S1, June 2015, Pages: S1–S567,

    Version of Record online : 12 JUN 2015, DOI: 10.1002/mds.26295

  5. The selective α1 adrenoceptor antagonist HEAT reduces L-DOPA-induced dyskinesia in a rat model of Parkinson's disease

    Synapse

    Volume 64, Issue 2, February 2010, Pages: 117–126, Kerstin Buck and Boris Ferger

    Version of Record online : 21 SEP 2009, DOI: 10.1002/syn.20709

  6. Histamine H3 receptor agonists reduce L-dopa–induced chorea, but not dystonia, in the MPTP-lesioned nonhuman primate model of Parkinson's disease

    Movement Disorders

    Volume 21, Issue 6, 6 June 2006, Pages: 839–846, Jordi Gomez-Ramirez, Tom H. Johnston, Naomi P. Visanji, Susan H. Fox and Jonathan M. Brotchie

    Version of Record online : 10 MAR 2006, DOI: 10.1002/mds.20828

  7. The α2 adrenergic antagonist fipamezole improves quality of levodopa action in Parkinsonian primates

    Movement Disorders

    Volume 25, Issue 13, 15 October 2010, Pages: 2084–2093, Tom H. Johnston, Susan H. Fox, Matthew J. Piggott, Juha-Matti Savola and Jonathan M. Brotchie

    Version of Record online : 7 SEP 2010, DOI: 10.1002/mds.23172

  8. The α2-adrenergic receptor antagonist idazoxan reduces dyskinesia and enhances anti-parkinsonian actions of L-dopa in the MPTP-lesioned primate model of Parkinson's disease

    Movement Disorders

    Volume 14, Issue 5, September 1999, Pages: 744–753, Brian Henry, Susan H. Fox, David Peggs, Alan R. Crossman and Jonathan M. Brotchie

    Version of Record online : 16 JAN 2001, DOI: 10.1002/1531-8257(199909)14:5<744::AID-MDS1006>3.0.CO;2-7

  9. You have free access to this content
    Poster Presentations

    Movement Disorders

    Volume 29, Issue S1, May 2014, Pages: S1–S571,

    Version of Record online : 6 JUN 2014, DOI: 10.1002/mds.25914

  10. Synergistic antidyskinetic effects of topiramate and amantadine in animal models of Parkinson's disease

    Movement Disorders

    Volume 26, Issue 13, November 2011, Pages: 2354–2363, Christopher Kobylecki, Michael P. Hill, Alan R. Crossman and Paula Ravenscroft

    Version of Record online : 23 SEP 2011, DOI: 10.1002/mds.23867

  11. You have free access to this content
    Abstracts of The Movement Disorder Society's Eleventh International Congress of Parkinson's Disease and Movement Disorders

    Movement Disorders

    Volume 22, Issue S16, 2007, Pages: S1–S325,

    Version of Record online : 24 APR 2007, DOI: 10.1002/mds.21535

  12. Topiramate reduces levodopa-induced dyskinesia in the MPTP-lesioned marmoset model of Parkinson's disease

    Movement Disorders

    Volume 20, Issue 4, April 2005, Pages: 403–409, Monty A. Silverdale, S.L. Nicholson, A.R. Crossman and J.M. Brotchie

    Version of Record online : 9 DEC 2004, DOI: 10.1002/mds.20345

  13. Serotonin transporter inhibition attenuates l-DOPA-induced dyskinesia without compromising l-DOPA efficacy in hemi-parkinsonian rats

    European Journal of Neuroscience

    Volume 36, Issue 6, September 2012, Pages: 2839–2848, Christopher Bishop, Jessica A. George, William Buchta, Adam A. Goldenberg, Mohamed Mohamed, Sando O. Dickinson, Satie Eissa and Karen L. Eskow Jaunarajs

    Version of Record online : 5 JUL 2012, DOI: 10.1111/j.1460-9568.2012.08202.x

  14. Poster session 2, Abstracts 345–694

    Movement Disorders

    Volume 19, Issue S9, 2004, Pages: S129–S244,

    Version of Record online : 10 MAY 2004, DOI: 10.1002/mds.20176

  15. 2nd World Parkinson Congress Abstracts

    Movement Disorders

    Volume 25, Issue S3, 15 September 2010, Pages: S569–S717,

    Version of Record online : 9 SEP 2010, DOI: 10.1002/mds.23386

    Corrected by:

    Erratum: Erratum

    Vol. 25, Issue 15, 2694, Version of Record online: 10 NOV 2010

  16. You have free access to this content
    Poster Session

    Movement Disorders

    Volume 31, Issue S2, June 2016, Pages: S1–S697,

    Version of Record online : 19 JUN 2016, DOI: 10.1002/mds.26688

  17. Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease

    European Journal of Neuroscience

    Volume 15, Issue 1, January 2002, Pages: 120–132, M. Lundblad, M. Andersson, C. Winkler, D. Kirik, N. Wierup and M. A. Cenci

    Version of Record online : 1 FEB 2002, DOI: 10.1046/j.0953-816x.2001.01843.x

  18. Therapies for dopaminergic-induced dyskinesias in parkinson disease

    Annals of Neurology

    Volume 69, Issue 6, June 2011, Pages: 919–927, Mildred D. Gottwald and Michael J. Aminoff

    Version of Record online : 16 JUN 2011, DOI: 10.1002/ana.22423

  19. Poster Session 3

    Movement Disorders

    Volume 21, Issue S15, September 2006, Pages: S517–S613,

    Version of Record online : 20 SEP 2006, DOI: 10.1002/mds.21248

  20. Idazoxan, an alpha-2 antagonist, and L-DOPA-induced dyskinesias in patients with Parkinson's disease

    Movement Disorders

    Volume 16, Issue 4, July 2001, Pages: 708–713, O. Rascol, I. Arnulf, H. Peyro-Saint Paul, C. Brefel-Courbon, M. Vidailhet, C. Thalamas, A.M. Bonnet, S. Descombes, B. Bejjani, N. Fabre, J.L. Montastruc and Y. Agid

    Version of Record online : 16 JUL 2001, DOI: 10.1002/mds.1143